Hero Background


AI solutions to help find the right next step for patients as early in their journey as possible

We are developing AI capabilities to help find actionable markers to identify potential therapeutic and clinical trial options for your patients.

Contact Us

The Tempus Edge platform leverages data and AI to identify therapeutic options for patients earlier in their journey

AI algorithms for molecular biomarker prediction

Our developing portfolio of digital pathology algorithms use a single whole slide H&E image to predict biomarkers, such as MSI or HRD status, for patients who are not ordinarily sequenced.

AI algorithms for clinical trial enrichment

Our algorithms are being developed to use an H&E whole slide image to identify patients likely to contain characteristics relevant for clinical trial eligibility through our unique biomarker prediction technology.

Solutions to digitize your practice

We can serve as a partner to your practice in digitizing your pathology workflow, from scanning to integrating algorithms into your existing workflow to uncover more potential options for patients.

Join our network of pathology labs to get access to these solutions

Our impact in oncology

  • 70+

    petabytes of data, which represents 25 times the size of the Cancer Genome Atlas

  • 5K+

    oncologists rely on Tempus as their precision medicine partner

  • 50%+

    of all Academic Medical Centers in the US are connected to Tempus

image description

Our Science


    Imaging-based histological features are predictive of MET alterations in Non-Small Cell Lung Cancer

    MET is a proto-oncogene whose somatic activation in non-small cell lung cancer leads to increased cell growth and tumor progression

    Read abstract

    2022 United States and Canadian Academy of Pathology (USCAP) Abstract

    Deep Learning Identifies Microsatellite Instability in H&E Whole Slide Images from Prostate, Esophageal, and Gastric Cancers and Generalizes across Cancer Types

    Read abstract

    2022 United States and Canadian Academy of Pathology (USCAP) Abstract

    Effects of Color Calibration via ICC Profile on Inter-scanner Generalization of AI Models

    Read abstract

    AI-augmented histopathologic review using image analysis to optimize DNA yield and tumor purity from FFPE slides

    AI-augmented histopathologic review using SmartPath could decrease tissue waste, sequencing time, and laboratory costs by optimizing DNA yields and tumor purity

    Read abstract

    Medical Image Computing and Computer Assisted Intervention – MICCAI 2021

    Deep Orthogonal Fusion: Multimodal Prognostic Biomarker Discovery Integrating Radiology, Pathology, Genomic, and Clinical Data

    Read abstract

Partnering with Tempus is investing in the future

We believe that AI solutions can open the door to more treatment options for patients by identifying actionable markers leading to potential novel therapies and clinical trials.